Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.

Molecular oncology - 1 Oct 2014

El-Chaar Nader N, Piccolo Stephen R, Boucher Kenneth M, Cohen Adam L, Chang Jeffrey T, Moos Philip J, Bild Andrea H

Abstract excerpt

Better approaches are needed to evaluate a single patient's drug response at the genomic level. Targeted therapy for signaling pathways in cancer has met limited success in part due to the exceedingly interwoven nature of the pathways. In particular, the highly complex RAS network has been challe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to ras Proteins

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 24908424
DOI: 10.1016/j.molonc.2014.05.005
PMCID: PMC4450766

Genes

EGFR
RPS6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24908424-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.PMID 24908424Read ↗

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read ↗

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.Semantic proximity Read ↗

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.Semantic proximity Read ↗

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Semantic proximity Read ↗

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.Semantic proximity Read ↗

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinomaSemantic proximity Read ↗

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.Semantic proximity Read ↗

Signaling networks assembled by oncogenic EGFR and c-MetSemantic proximity Read ↗

Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic TargetsSemantic proximity Read ↗

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.Semantic proximity Read ↗

Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.Semantic proximity Read ↗

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.